Stambolliu, E.; Ioakeim-Ioannidou, M.; Kontokostas, K.; Dakoutrou, M.; Kousoulis, A.A. (2017) This review aimed at reporting its main non-neurological comorbidities. METHODS: Following PRISMA guidelines, search in Medline was conducted (2000-2014, keyword dandywalker). Age, sex, country, DWS type, consanguinity or siblings with DWS, and recorded coexistent conditions (by ICD10 category) were extracted for 187 patients (46.5% male, 43% from Asia) from 168 case reports. RESULTS: Diagnosis was most often set in <1y.o. (40.6%) or >12y.o. (27.8%). One-third of cases had a chromosomal abnormality or syndrome (N=8 PHACE), 27% had a cardiovascular condition (N=7 Patent Ductus Arteriosus), 24% had a disease of eye and ear (N=9 cataract); most common malignancy was nephroblastoma (N=8, all Asian). Almost one-fifth had a mental illness diagnosis; only 6.4% had mild or severe intellectual disability. CONCLUSION: The spread of comorbidities calls for early diagnosis and multidisciplinary research and practice, especially as many cases remain clinically asymptomatic for years.

No abstract

No abstract

Objective: The current study reviewed the published evidence on the seasonal changes in blood pressure (BP) assessed using different measurement methods. Methods: A systematic PubMed/EMBASE search was performed for studies assessing seasonal BP changes. Prospective and cross-sectional studies were included fulfilling the following criteria: (i) report of ambulatory and/or home BP data; (ii) cross-sectional studies reporting only office BP measurements and including 1000 or more participants. Results: Forty-seven studies fulfilled the selection criteria and were included (856 539 participants, weighted age 49.7 ± 4.8 years, 38.8% treated hypertensive patients). The pooled summer minus winter SBP/DBP difference (95% confidence intervals) was office BP (29 studies) −5.6 (−7.1, −4.0)/−3.3 (−4.0, −2.7) mmHg; daytime ambulatory BP (15 studies) −3.4 (−4.4, −2.4)/−2.1 (−2.8, −1.4) mmHg; night-time ambulatory BP (13 studies) 1.3 (0.2, 2.3)/0.5 (−0.2, 1.2) mmHg; home BP (9 studies) −6.1 (−7.0, −5.1)/−3.1 (−3.5, −2.6) mmHg. Meta-analysis of 28 prospective studies (N = 5278) which examined the same individuals during different seasons showed pooled seasonal SBP/DBP difference: office BP −5.8/−4.0 mmHg; daytime ambulatory BP −3.9/−2.7 mmHg; night-time ambulatory BP 0.5/−0.5 mmHg; home BP −6.4 /−3.3 mmHg. In meta-regression analysis seasonal systolic daytime ambulatory BP difference was related to the percentage of treated hypertensive patients across studies (P = 0.02) and borderline to age (P = 0.07). Conclusion: Seasonal BP changes are evident using all daytime BP measurement methods, but not with night-time ambulatory BP. The average BP decline in hot season is at about 5/3 (SBP/DBP) mmHg and appears to be larger in treated hypertensive patients and in older individuals.

Additional supporting information may be found online in the Supporting Information section at the end of the article. How to cite this article: Kollias A, Stambolliu E, Kyriakoulis KG, Gravvani A, Stergiou GS. Unattended versus attended automated office blood pressure: Systematic review and meta-analysis of studies using the same methodology for both methods. J Clin Hypertens. 2019;21:148-155. https://doi.

The professional Microlife WatchBP Office BP monitor fulfilled the requirements of the ANSI/AAMI/ISO validation standard for adults and children and can be recommended for clinical use.

Blood pressure (BP) is a vital sign, and its measurement is essential for diagnosing and treating hypertension. The accuracy of BP monitors is therefore essential, but unfortunately very few devices available on the market have been validated using an established protocol. STRIDE BP (www.strid ebp.org) is an international nonprofit organization with the mission to improve the accuracy of BP measurement and the diagnosis of hypertension. It has a prestigious Scientific Advisory Board and operates in affiliation with the European Society of Hypertension, the International Society of Hypertension, and the World Hypertension League. STRIDE BP provides lists of accurate office, ambulatory, and home BP monitors. STRIDE BP performed a systematic review of 419 published validations (270 articles and 260 devices). In these publications, 50 (12%) of the validations were rejected compared with 129 (31%) rejected by STRIDE BP (P < .001). Of 79 validations approved in publications but rejected by STRIDE BP, 7 (9%) were rejected due to device inaccuracy and 72 (91%) due to inadequate study quality (execution, analysis, and reporting). Errors in conducting and reporting published validations must be avoided. Peer review must ascertain that a comprehensive checklist of all aspects of a validation study have been adhered to. The implementation of a Universal Standard for device validation and the global dissemination of information on accurate devices by STRIDE BP are expected to improve the quality and accuracy of BP measurement, which should have a positive impact on the diagnosis and management of hypertension globally. | 1617 STERGIOU ET al.

Background Current evidence indicates that statins increase the risk of new onset diabetes mellitus (NOD) and also deteriorate the glycemic control in patients with known diabetes mellitus (DM) after high-dose statin therapy. Aims The aim of this review was to explore the effect of atorvastatin in causing NOD or deteriorating glycemic control in patients with DM. Methods Two independent reviewers conducted the literature search, through PubMed database searching for articles published in English until April 2015, and only primary studies were included. Results Of the 919 articles identified in our original search, 33 met the criteria for this review encompassing 1,951,113 participants. Twenty articles examined dysregulation of DM due to atorvastatin. Half of them showed that there was no significant change in glycemic control in patients treated with atorvastatin. Other studies showed that fasting plasma glucose and HbA1c levels were increased by atorvastatin. Thirteen articles examined if atorvastatin causes NOD. The majority of these articles showed that patients who used atorvastatin had a higher dose-dependent risk of developing NOD. Conclusion This systematic review suggests that there is an association between atorvastatin treatment and NOD. Moreover, it showed that atorvastatin in high dose causes worsening of the glycemic control in patients with DM.